secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0001104659-25-021379
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics FY2024 cash $11.6M; VCN-01 Phase 2b data due Q2 2025
----------------------------------------------------------------------

- Cash and cash equivalents $11.6M as of Dec 31, 2024; expected runway into Q3 2025.
- R&D expenses decreased 16% to $12.0M; G&A expenses increased 4% to $7.4M.
- VIRAGE Phase 2b enrollment completed (92 evaluable patients); topline data expected Q2 2025.
- FDA Fast Track for VCN-01 in PDAC; FDA and EMA provided Phase 3 trial design guidance.
- Audited 10-K includes going concern explanatory paragraph from independent auditor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465925021379/0001104659-25-021379-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465925021379/tm258283d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-021379

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer